DNA and RNA vaccines represent groundbreaking advancements in vaccination technology. Unlike traditional vaccines that use weakened or inactivated viruses, DNA and RNA vaccines work by introducing genetic material (DNA or RNA) from the pathogen into the body. Once inside, the body's cells use this genetic material to produce a harmless part of the virus, triggering an immune response. These vaccines are highly adaptable, allowing for rapid development to combat emerging diseases like COVID-19. DNA vaccines deliver a small, circular DNA strand, while RNA vaccines use messenger RNA to instruct cells to create viral proteins. Both types are safe, efficient, and offer promising avenues for combating infectious diseases while potentially revolutionizing future vaccine development.
Regina Au
BioMarketing Insight, United States
Khursheed Anwer
IMUNON, Inc., United States
Joe Smyser
The Public Good Projects, United States
Vincenzo Alfano
University of Napoli Parthenope, Italy
Carly Contri
American Academy of Pediatrics, United States
Khursheed Anwer
IMUNON, Inc., United States
Sean Yanik
Johns Hopkins, United States
Yen Hung Chow
National Health Research Institutes, Taiwan
Ping Xie
Associate Professor , United StatesSubmit your abstract Today
Title : Evaluating community-based vaccine initiatives with power BI
Carly Contri, American Academy of Pediatrics, United States
Title : The power of cultural validation when empowering community immunity
Julissa Soto, Julissa Soto Latino Health Equity Consulting, United States
Title : High prevalence of zero-dose children in underserved and special setting populations in Ethiopia using a generalize estimating equation and concentration index analysis.
Gashaw Andargie Biks, Project HOPE, Ethiopia
Title : Your vaccine attitude determines your altitude. What are the determinants of attitudes toward vaccination
Vincenzo Alfano, University of Napoli Parthenope, Italy
Title : Current Investments and Future Directions of Biomedical Advanced Research and Development Authority’s CBRN Vaccines Portfolio
Lindsay Parish, BARDA, United States
Title : Evaluation of vaccine preventable disease VPD surveillance system in Haryana state, India.
Prasoon Sheoran, Directorate of Health and Family Welfare, India
Title : Adaptation of local rabies virus isolates to high growth titer to develop vaccine strain in Ethiopia
Abebe Aga, Armauer Hansen Research Institute, Ethiopia
Title : Antibiotic resistance present situation in Bangladesh at different districts
Ismail Hossain, Globe Biotech, Bangladesh
Title : Spatial distribution of zero-dose children in Ethiopia: Evidence for a targeted intervention from a large-scale evaluation survey
Fisseha Shiferie Tadesse, Project HOPE, Ethiopia
Title : Impact of vaccination on the risk of severe forms of COVID -19 among elderly patients hospitalized in a Tunisian university hospital
Souhir Ayadi, Faculty of Medicine, Tunisia